MedTrace Logo

Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease

NCT03136679 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2026-01-26

No results posted yet for this study

Summary

This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center. The aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive impairment associated with Alzheimer's disease. Subjects will also be screened for B-vitamin deficiencies that may correlate with other metabolic biomarkers and Alzheimer's disease.

Conditions

Sponsors & Collaborators

  • Baylor Research Institute

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-22
Primary Completion
2021-11-24
Completion
2021-11-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03136679 on ClinicalTrials.gov